Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1NET 1Endocrine 1

Conditions

Colorectal Neoplasms 15Stomach Neoplasms 11Colonic Neoplasms 7Carcinoma, Hepatocellular 7Rectal Neoplasms 4Pancreatic Neoplasms 3Neoplasms 3Biliary Tract Neoplasms 3Lymphoma, Large B-Cell, Diffuse 2Gastrointestinal Neoplasms 2Gallbladder Neoplasms 2Adenocarcinoma 2Vipoma 1Somatostatinoma 1Resected Liver Metastases From Colorectal Cancer 1Recurrence 1Quality of Life 1Pathologic Complete Response 1Neuroendocrine Tumors 1Neoplasm Metastasis 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Liver Neoplasms 1Insulinoma 1Immunotherapy Gastrict Cancer 1HER2-positive Gastric Cancer 1Glucagonoma 1Gastroesophageal Junction Adenocarcinoma 1Gastrinoma 1Esophageal Squamous Cell Carcinoma 1

Interventions

Oxaliplatin 1Leucovorin 1Fluorouracil 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Vipoma × Oxaliplatin × Clear all
NCT00227617 2023-05-22

Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors

University of California, San Francisco

Phase 2/3 Terminated
36 enrolled 14 charts
EndocrineNETThoracic

Vipoma, Glucagonoma, Insulinoma, Adenoma, Islet Cell, Lung Neoplasms, Neoplasms, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡